Acelyrin Inc.’s shares tumbled after its interleukin-17A inhibitor, izokibep, failed to reach statistical significance in part B of a phase IIb/III trial in moderate to severe hidradenitis suppurativa (HS), but the company remains undeterred with its plans to advance the drug for the inflammatory skin condition.